Innate Pharma Files its 2020 Universal Registration Document (Document d’Enregistrement Universel) and 2020 Annual Report on Form 20-F

On April 28, 2021 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") reported the filing of its 2020 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2020 with the French market authority "Autorité des Marchés Financiers" ("AMF") on April 27, 2021 (Press release, Innate Pharma, APR 28, 2021, View Source [SID1234578602]). It can be downloaded (in French) on the Company’s website and on the AMF’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company also announced today the filing of its annual report on Form 20-F for the year ending December 31, 2020 with the United States Securities and Exchange Commission ("SEC"). It can be also be accessed on the Company’s website and on the SEC’s website.